Overview

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

Status:
RECRUITING
Trial end date:
2031-01-16
Target enrollment:
Participant gender:
Summary
A study to evaluate the long-term safety of Deucravacitinib versus Ustekinumab in participants with psoriasis
Phase:
PHASE3
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
deucravacitinib
Ustekinumab